Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study

Publication date: Available online 12 August 2017
Source:Clinical Therapeutics
Author(s): Yundai Chen, Dandan Li, Jing Jing, Hongbing Yan, Jinghua Liu, Zhujun Shen, Stefan James, Christoph Varenhorst
PurposeLimited data exist on the use of statins in Chinese patients with coronary artery disease (CAD) treated with percutaneous coronary intervention (PCI). We therefore conducted this study to observe the usage trend and the effectiveness of statins on LDL-C goal attainment and other lipid parameters among PCI-treated patients.MethodsThis multicenter, retrospective, observational, longitudinal cohort study was conducted in PCI-treated patients with CAD between July 1, 2011, and February 28, 2015. Primary study outcomes included statin treatment pattern after PCI and proportion of patients achieving target (LDL-C) levels 1 month after PCI and initiating statin therapy.FindingsData were analyzed for 2708 patients (mean age, 59 [10] years; median body mass index, 25.6 [4.0] kg/m²). From baseline to the end of 1 month, atorvastatin and rosuvastatin were the most prescribed statins; 20 mg and 10 mg were the most prescribed doses and therefore chosen for efficacy comparisons. In patients without dose changes, LDL-C reduction with rosuvastatin 10 mg was significantly greater compared with atorvastatin 20 mg (–0.67 mmol/L [from 2.44 mmol/L to 1.77 mmol/L] vs –0.54 mmol/L [from 2.40 mmol/L to 1.86 mmol/L]; P = 0.008). However, there was no difference in HDL-C, triglyceride, or total cholesterol values between groups. Age and LDL-C levels at baseline were significantly associated with target LDL-C achievement.ImplicationsIn real-world, PCI-treated Chinese patients, atorvastatin and rosuvastatin were the most prescribed statins. Compared with atorvastatin 20 mg, rosuvastatin 10 mg was associated with greater LDL-C reductions and achievement of LDL-C targets in a higher percentage of patients. This analysis of real-world data shows that both rosuvastatin and atorvastatin were well tolerated and seemed to be suitable drugs for controlling lipid levels and preventing CVD risk in post-PCI Chinese patients with CAD.



http://ift.tt/2vL0TC7